Targeted SCFA delivery
The company delivers targeted SCFAs to gut epithelial cells and the blood-brain barrier.
Source: LinkedIn company description · Retrieved October 13, 2026
PLL Therapeutics is a clinical-stage biopharmaceutical company founded in 2019.
The company focuses on restoring gut integrity by delivering targeted SCFAs to gut epithelial cells. PLL Therapeutics is validating a panel of biomarkers for clinical use in early-stage ALS diagnosis.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company delivers targeted SCFAs to gut epithelial cells and the blood-brain barrier.
Source: LinkedIn company description · Retrieved October 13, 2026
The diagnostic development includes companion diagnostics for ALS and other neurodegenerative disorders.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 3, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026, September 18, 2026 and September 19, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.